Els De Paepe
About
Els De Paepe is a scholar working on Infectious Diseases, Epidemiology and Pediatrics, Perinatology and Child Health.
According to data from OpenAlex, Els De Paepe has authored 28 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Infectious Diseases, 13 papers in Epidemiology and 7 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Els De Paepe's work include HIV/AIDS drug development and treatment (15 papers), Respiratory viral infections research (11 papers) and Pharmacological Effects and Toxicity Studies (7 papers). Els De Paepe is often cited by papers focused on HIV/AIDS drug development and treatment (15 papers), Respiratory viral infections research (11 papers) and Pharmacological Effects and Toxicity Studies (7 papers). Els De Paepe collaborates with scholars based in Belgium, Netherlands and United States. Els De Paepe's co-authors include Tine De Marez, Éric Lefebvre, Tony Vangeneugden, Martin P. Grobusch, Vaira Leimane, Eduardo Gotuzzo, Nyasha Bakare, Andreas H. Diacon, Rolf P. G. van Heeswijk and Nacer Lounis and has published in prestigious journals such as New England Journal of Medicine, Journal of Virology and The Journal of Infectious Diseases.
In The Last Decade
Els De Paepe
28 papers receiving 1.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Els De Paepe Belgium | 15 | 964 | 679 | 248 | 163 | 147 | 28 | 1.2k | ||
| Getachew Aderaye Ethiopia | 24 | 1.1k 1.1× | 806 1.2× | 181 0.7× | 347 2.1× | 126 0.9× | 51 | 1.6k | ||
| Denise Pui Chung Chan Hong Kong | 19 | 453 0.5× | 651 1.0× | 148 0.6× | 178 1.1× | 106 0.7× | 56 | 1.2k | ||
| Awewura Kwara United States | 26 | 1.1k 1.2× | 696 1.0× | 331 1.3× | 211 1.3× | 108 0.7× | 86 | 1.6k | ||
| Rosa María López Spain | 18 | 534 0.6× | 326 0.5× | 134 0.5× | 126 0.8× | 103 0.7× | 44 | 888 | ||
| R. Garraffo France | 19 | 555 0.6× | 313 0.5× | 359 1.4× | 120 0.7× | 104 0.7× | 92 | 1.3k | ||
| Chandrasekaran Padmapriyadarsini India | 23 | 1.2k 1.2× | 786 1.2× | 123 0.5× | 353 2.2× | 98 0.7× | 110 | 1.6k | ||
| Gregory P. Bisson United States | 23 | 1.4k 1.4× | 1000 1.5× | 352 1.4× | 317 1.9× | 163 1.1× | 70 | 1.9k | ||
| Giorgio Gatti Italy | 16 | 837 0.9× | 390 0.6× | 316 1.3× | 58 0.4× | 101 0.7× | 38 | 1.2k | ||
| Giuliano Rizzardini Italy | 15 | 800 0.8× | 341 0.5× | 539 2.2× | 60 0.4× | 130 0.9× | 39 | 1.3k | ||
| Lillian Ting Canada | 15 | 537 0.6× | 273 0.4× | 303 1.2× | 96 0.6× | 146 1.0× | 26 | 1.1k |
Countries citing papers authored by Els De Paepe
Since
Specialization
Citations
This map shows the geographic impact of Els De Paepe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Els De Paepe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Els De Paepe more than expected).
Fields of papers citing papers by Els De Paepe
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Els De Paepe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Els De Paepe. The network helps show where Els De Paepe may publish in the future.
Co-authorship network of co-authors of Els De Paepe
This figure shows the co-authorship network connecting the top 25 collaborators of Els De Paepe. A scholar is included among the top collaborators of Els De Paepe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Els De Paepe. Els De Paepe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bastian, Arangassery Rosemary, Ilse Scheys, Els De Paepe, et al.. (2023). Concomitant Administration of Ad26.RSV.preF/RSV preF Protein Vaccine and High-Dose Influenza Vaccine in Adults 65 Years and Older: A Noninferiority Trial. The Journal of Infectious Diseases. 230(2). e374–e383.
2.
Osborne, Richard H., Lauren Nelson, Sheri Fehnel, et al.. (2023). Evaluation of symptoms in respiratory syncytial virus infection in adults: psychometric evaluation of the Respiratory Infection Intensity and Impact Questionnaire™ symptom scores. Journal of Patient-Reported Outcomes. 7(1). 51–51.
3.
Comeaux, Christy, Stephan Bart, Arangassery Rosemary Bastian, et al.. (2023). Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF–Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study. The Journal of Infectious Diseases. 229(1). 19–29.
4.
Bartsch, Yannic C., Deniz Cizmeci, Dansu Yuan, et al.. (2023). Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine. Journal of Virology. 97(11). e0077123–e0077123.
5.
Falsey, Ann R., Kristi L. Williams, Stephan Bart, et al.. (2021). LB14. Efficacy and Immunogenicity of an Ad26.RSV.preF-based Vaccine in the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase 2b Study. Open Forum Infectious Diseases. 8(Supplement_1). S812–S812.
6.
Sadoff, Jerald, Els De Paepe, Wouter Haazen, et al.. (2020). Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults. The Journal of Infectious Diseases. 223(4). 699–708.
7.
Diacon, Andreas H., Alexander S. Pym, Martin P. Grobusch, et al.. (2014). Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline. New England Journal of Medicine. 371(8). 723–732.
8.
Heeswijk, Rolf van, Pieter Verboven, Jan Snoeys, et al.. (2013). Pharmacokinetic Interaction between Telaprevir and Methadone. Antimicrobial Agents and Chemotherapy. 57(5). 2304–2309.
9.
Kakuda, Thomas N., Vanitha Sekar, Ludo Lavreys, et al.. (2013). Pharmacokinetics of darunavir after administration of an oral suspension with low‐dose ritonavir and with or without food. Clinical Pharmacology in Drug Development. 3(5). 346–352.
10.
Boogaerts, Griet, et al.. (2012). Bioavailability of the HCV NS3/4A Protease Inhibitor Telaprevir–Effect of Different Types of Food. Zeitschrift für Gastroenterologie. 50(1).
11.
Boogaerts, Griet, et al.. (2011). Pharmakokinetik des Proteaseinhibitors Telaprevir bei schwerer Niereninsuffizienz. Zeitschrift für Gastroenterologie. 49(8).
12.
Sekar, Vanitha, Sabrina Spinosa‐Guzman, Els De Paepe, et al.. (2010). Pharmacokinetics of Multiple-Dose Darunavir in Combination with Low-Dose Ritonavir in Individuals with Mild-to-Moderate Hepatic Impairment. Clinical Pharmacokinetics. 49(5). 343–350.
13.
Sekar, Vanitha, Éric Lefebvre, Tine De Marez, et al.. (2010). Pharmacokinetic Interaction between Indinavir and Darunavir with Low-Dose Ritonavir in Healthy Volunteers. Intervirology. 53(3). 176–182.
14.
Meyer, Sandra De, Erkki Lathouwers, Inge Dierynck, et al.. (2009). Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. AIDS. 23(14). 1829–1840.
15.
Sekar, Vanitha, et al.. (2009). Bioavailability and food effect of darunavir following administration of an oral suspension.
16.
Meyer, Sandra De, Tony Vangeneugden, Ben Van Baelen, et al.. (2008). Resistance Profile of Darunavir: Combined 24-Week Results from the POWER Trials. AIDS Research and Human Retroviruses. 24(3). 379–388.
17.
Lefebvre, Éric, et al.. (2008). Effect of Repeated Doses of Darunavir plus Low-Dose Ritonavir on the Pharmacokinetics of Sildenafil in Healthy Male Subjects. Clinical Drug Investigation. 28(8). 479–485.
18.
Meyer, Sandra De, Erkki Lathouwers, Inge Dierynck, et al.. (2008). O424 Resistance development in virological failures with DRV/r or LPV/r: 96-week analysis of the Phase III TITAN trial in treatment-experienced patients. Journal of the International AIDS Society. 11(Suppl 1). O46–O46.
19.
Sekar, Vanitha, Sabrina Spinosa‐Guzman, Martine De Pauw, et al.. (2007). The Effect of Different Meal Types on the Pharmacokinetics of Darunavir (TMC114)/Ritonavir in HIV‐Negative Healthy Volunteers. The Journal of Clinical Pharmacology. 47(4). 479–484.
20.
Sekar, Vanitha, Éric Lefebvre, Tine De Marez, et al.. (2007). Pharmacokinetics of Darunavir (TMC114) and Atazanavir during Coadministration in HIV-Negative, Healthy Volunteers. Drugs in R&D. 8(4). 241–248.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Getachew Aderaye Breakdown of academic impact, for papers by Denise Pui Chung Chan Breakdown of academic impact, for papers by Awewura Kwara Breakdown of academic impact, for papers by Rosa María López Breakdown of academic impact, for papers by R. Garraffo Breakdown of academic impact, for papers by Chandrasekaran Padmapriyadarsini Breakdown of academic impact, for papers by Gregory P. Bisson Breakdown of academic impact, for papers by Giorgio Gatti Breakdown of academic impact, for papers by Giuliano Rizzardini Breakdown of academic impact, for papers by Lillian Ting